Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 11/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19532870 | 0.85 | CA2 (0.40) | GABRA1ARPDK2PDK1PDK3 | |
| SCHEMBL25814826 | 0.81 | TSHR (0.36) | ARPDK2PDK1PDK3PDK4 | |
| SCHEMBL9034853 | 0.80 | TSHR (0.46) | ARPDK2PDK1PDK3PDK4 | |
| SCHEMBL30619339 | 0.80 | TSHR (0.46) | ARPDK2PDK1PDK3PDK4 | |
| SCHEMBL2003310 | 0.79 | AR (0.46) | ARSLC22A12 | |
| SCHEMBL1533157 | 0.75 | TSHR (0.46) | PDK2NOTUMTSHRMCL1 | |
| SCHEMBL27176564 | 0.74 | NOTUM (0.41) | ARPDK2PDK1PDK3PDK4 | |
| SCHEMBL30708060 | 0.74 | NOTUM (0.41) | ARPDK2PDK1PDK3PDK4 | |
| SCHEMBL1064239 | 0.72 | ALDH1A1 (0.46) | GABRA1TSHRHSD11B1 | |
| SCHEMBL23412139 | 0.71 | CA2 (0.37) | GABRA1PDK2PDK1PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740655-B2 | 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4-SPECIFIC INHIBITORS REDUCE EOSINOPHIL INFLUX TO THE LUNGS; SIDE EFFECT REDUCTION; ANTIINFLAMMATORY AGENT; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS, ESPECIALLY ASTHMA | PFIZER INC | 2004-05-25 | — | — | US | disclosed |
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PFIZER PRODUCTS INC. | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PDE12, PDE4A, PDE4B | GABRA1 2901/4885GABRG2 3716/4885GABRB3 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.